DOR Extension of Letter of Intent with Gastrotech
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported): December
29, 2005
Commission
File No. 1-14778
DOR
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
|
DELAWARE
|
|
41-1505029
|
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification Number)
|
| |
|
|
|
1691
Michigan Ave., Suite 435
Miami,
FL
|
|
33139
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
| |
(305)
534-3383
|
|
| |
(Issuer’s
telephone number, including area code)
|
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
|
Item
1.01.
|
Entry
into a Material Definitive
Agreement.
|
As
previously reported, on October 28, 2005, DOR BioPharma, Inc. (the “Company”)
entered into a Binding Letter of Intent (the “Letter”) to acquire Gastrotech
Pharma A/S (“Gastrotech”), a private Danish biotechnology company developing
therapeutics based on gastrointestinal peptide hormones to treat
gastrointestinal and cancer diseases and conditions. On December 29, 2005,
the
parties amended the Letter to extend the termination date of the Letter and
the
exclusivity period provided by the Letter to January 15, 2006.
A
copy of
the amendment to the Letter between the Company and Gastrotech is filed as
Exhibit 10.1 to this Current Report on Form 8-K.
Item
9.01. Financial Statements and Exhibits.
(c)
Exhibits.
Exhibit
No. Title
10.1 Amendment
to Binding Letter of Intent dated December 29, 2005 between the Company and
Gastrotech.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
DOR
BIOPHARMA, INC.
By:
/s/
Michael T. Sember
Name:
Michael T. Sember
Title:
President and Chief Executive Officer
Dated: January
3, 2006
Exhibit
Index
Exhibit
Number Description
of Exhibits
10.1 Amendment
to Binding Letter of Intent dated December 29, 2005 between the Company and
Gastrotech.